Q-omics provides the consensus-scored ZNF136 profile across patient tissues and cancer cell-line models. ZNF136 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF136 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, ZNF136 RNA expression shows 21,735 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, LUAD, and KIRP as cancer lineages where ZNF136 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF136 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF136 survival associations across molecular data types. ZNF136 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF136 RNA expression–survival associations across cancer types. High ZNF136 expression shows unfavorable associations in UVM and LUSC, but favorable associations in KIRC, HNSC, LUAD and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF136 RNA expression.
This table summarizes ZNF136 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF136. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF136 shows lower tumor expression in LUAD, THCA, LUSC and UCEC and higher tumor expression in LIHC and CHOL. The LUAD box plot shows higher ZNF136 RNA expression in normal versus tumor tissue (log2 FC = −0.747, t-test p < 0.001).
This table shows molecular features associated with ZNF136 in patient tissues and cancer cell lines. In patient samples, ZNF136 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF136 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
